Consensus on the use and monitoring of anti-TNF-α therapies for rheumatic diseases in Hong Kong 2005

APLAR Journal of Rheumatology

Volumn 9, Issue 2, 2006, Pages 175-180

  Mok, Chi Chiu ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Biologics; Guideline; Recommendation; Registry; TNF

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BLOOD TOXICITY; BREAST FEEDING; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCEPTION; CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; COUGHING; DEMYELINATING DISEASE; DISEASE EXACERBATION; DISEASE REGISTRY; DISEASE SEVERITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG USE; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEVER; HEMOPTYSIS; HEPATITIS B; HEPATITIS C; HONG KONG; HUMAN; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MEDICAL SOCIETY; MILIARY TUBERCULOSIS; MONOTHERAPY; MULTIPLE SCLEROSIS; NIGHT SWEAT; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PATIENT MONITORING; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SIDE EFFECT; SKIN INFLAMMATION; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THORAX RADIOGRAPHY; TUBERCULIN TEST; WEIGHT REDUCTION;

EID: 33745937104     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00194.x     Document Type: Article

References (25)

1. Lipsky PE, van der Heijde DM, St Clair EW, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594-602.
2. Klareskog L, van der Heijde D, de Jager JP, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363, 675-81.
3. Bathon JM, Martin RW, Fleischmann RM, et al. (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343, 1586-93.
4. Keystone EC, Kavanaugh AF, Sharp JT, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400-11.
5. Breedveld FC, Emery P, Keystone E, et al. (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63, 149-55.
6. Lovell DJ, Giannini EH, Reiff A, et al. (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatol Collaborative Study Group. N Engl J Med 342, 763-9.
7. Braun J, Brandt J, Listing J, et al. (2002) Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359, 1187-93.
8. Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346, 1349-56.
9. Brandt J, Khariouzov A, Listing J, et al. (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48, 1667-75.
10. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 356, 385-90.
11. Mease PJ, Kivitz AJ, Burch FX, et al. (2004) Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 50, 2264-72.
12. Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 30, 257-70, v.
13. Imperato AK, Smiles S, Abramson SB (2004) Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 16, 199-205.
14. Hamilton CD (2003) Tuberculosis in the cytokine era: What rheumatologists need to know. Arthritis Rheum 48, 2085-91.
15. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27, 361-8.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21, 2286-91.
17. Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3, 55-78.
18. Michel M, Duvoux C, Hezode C, Cherqui D (2003) Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 30, 1624-5.
19. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62, 686-7.
20. Oniankitan O, Duvoux C, Challine D, et al. (2004) Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31, 107-9.
21. Peterson JR, Hsu FC, Simkin PA, Wener MH (2003) Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62, 1078-82.
22. Cohen JD, Zaltni S, Kaiser MJ, et al. (2004) Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis 63, 209-10.
23. Klareskog L, van der Heijde D, de Jager JP, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363, 675-81.
24. van Vollenhoven R, Harju A, Brannemark S, Klareskog L (2003) Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: Data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 62, 1195-8.
25. Ang HT, Helfgott S (2003) Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol 30, 2315-8.